Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Forty Seven Inc (FTSV)

Forty Seven Inc (FTSV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 610,465
  • Shares Outstanding, K 42,276
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,370 K
  • 60-Month Beta 2.49
  • Price/Sales 30.75
  • Price/Cash Flow N/A
  • Price/Book 3.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.72
  • Number of Estimates 4
  • High Estimate -0.64
  • Low Estimate -0.83
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.84 +84.18%
on 11/08/19
14.62 -1.23%
on 12/05/19
+6.43 (+80.27%)
since 11/06/19
3-Month
5.53 +161.12%
on 10/23/19
14.62 -1.23%
on 12/05/19
+6.97 (+93.31%)
since 09/06/19
52-Week
5.53 +161.12%
on 10/23/19
23.83 -39.40%
on 12/14/18
-3.97 (-21.56%)
since 12/06/18

Most Recent Stories

More News
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

PTH : 91.63 (+0.87%)
PBE : 54.96 (+1.14%)
XBI : 94.43 (+1.23%)
CNCR : 23.55 (+0.66%)
DXCM : 224.76 (-0.90%)
CLVS : 9.61 (+8.47%)
BIIB : 300.26 (+0.29%)
PTI : 3.55 (-6.33%)
AQST : 8.01 (-3.96%)
FTSV : 14.44 (+2.12%)
ARKG : 34.59 (+1.44%)
Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights

-- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 --

FTSV : 14.44 (+2.12%)
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based...

BLUE : 79.42 (-1.53%)
FTSV : 14.44 (+2.12%)
Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its...

FTSV : 14.44 (+2.12%)
Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference...

FTSV : 14.44 (+2.12%)
Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference

Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D.,...

FTSV : 14.44 (+2.12%)
Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that the U.S. Food and Drug Administration...

FTSV : 14.44 (+2.12%)
Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D.,...

MS : 49.80 (+1.49%)
FTSV : 14.44 (+2.12%)
Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights

-- Presented Updated Data for 5F9 in Four Patient Populations at ASCO and EHA Meetings --

FTSV : 14.44 (+2.12%)
Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome

Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced additional funding commitments from The...

FTSV : 14.44 (+2.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade FTSV with:

Business Summary

Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition...

See More

Key Turning Points

2nd Resistance Point 15.13
1st Resistance Point 14.79
Last Price 14.44
1st Support Level 13.77
2nd Support Level 13.09

See More

52-Week High 23.83
Fibonacci 61.8% 16.84
Fibonacci 50% 14.68
Last Price 14.44
Fibonacci 38.2% 12.52
52-Week Low 5.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar